Benjamin Yaden

Benjamin Yaden currently serves as the VP of External Innovation for Diabetes, Obesity, and Cardiometabolic Diseases at Eli Lilly and Company, where they lead global initiatives to identify novel preclinical and clinical assets. With 20 years of experience in drug discovery across various disease areas, Benjamin has held multiple roles at Eli Lilly, contributing significantly to the development of targets and partnerships. They obtained both a master’s degree and a Ph.D. in Endocrinology from Purdue University, where they now also serve as an adjunct professor and mentor students in advanced research. Benjamin continues to collaborate with experts in hepatology, focusing on mechanisms related to liver and muscle injury.